Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to ...

This is where Allurion’s unique approach comes into play. Previous studies have demonstrated that patients using the Allurion Gastric Balloon in combination with the Allurion Virtual Care Suite ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose ...

550 subjects were randomized 1:1 to either two cycles of the Allurion Balloon 1 or a control group that received moderate intensity lifestyle therapy. Subjects in the treatment group received ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 ...

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable ...